|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:CureVac_AG
|
|
gptkbp:businessModel
|
research and development
biopharmaceuticals
commercialization
|
|
gptkbp:CEO
|
gptkb:Robert_Forrester
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:Canada
gptkb:United_States
Europe
Phase 1
Phase 3
solid tumors
hematologic malignancies
Phase 2 trials
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
|
|
gptkbp:focus
|
cancer treatment
|
|
gptkbp:founded
|
2010
|
|
gptkbp:founder
|
gptkb:Robert_Forrester
|
|
gptkbp:funding
|
public offerings
private placements
|
|
gptkbp:hasPrograms
|
experts in oncology
|
|
gptkbp:headquarters
|
gptkb:Needham,_Massachusetts
|
|
gptkbp:historicalResearch
|
gptkb:NCI
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Verastem
|
|
gptkbp:investmentFocus
|
Venture capital firms
|
|
gptkbp:leadership
|
experienced executives
|
|
gptkbp:market
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:mission
|
improve cancer treatment
|
|
gptkbp:partnerships
|
gptkb:Merck
gptkb:AstraZeneca
|
|
gptkbp:products
|
Duvelisib
VS-6766
|
|
gptkbp:regulatoryCompliance
|
FDA_approval
EMA_approval
|
|
gptkbp:research
|
PI3K_pathway
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:researchFocus
|
tumor microenvironment
cancer stem cells
|
|
gptkbp:stockSymbol
|
VSTM
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:tributaryOf
|
multiple drug candidates
|
|
gptkbp:type
|
public company
|
|
gptkbp:vision
|
transform cancer care
|
|
gptkbp:website
|
www.verastem.com
|